/
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease often with limited or no therapeutic options.
The business is unprofitable at the operating level (-10.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.9%, steady but not accelerating. Margins contracted 27.7pp, which offsets some of the top-line progress.
ROIC dropped from 5.72% to -3.40%, capital efficiency is deteriorating. Operating margin contracted 27.7pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$4.44B
▲ +4.9% YoY
Net Income (TTM)
$29M
▼ -163.6% YoY
Op. Margin
-0.85%
▼ -27.7pp YoY
ROIC
-0.31%
▼ -9.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.27B
▼ -4.5% YoY
Op. Cash Flow (TTM)
$1.33B
▼ -2.9% YoY
Net Debt
$3.56B
Cash & Equiv.
$1.84B
5Y CAGR: +12.5%
5Y CAGR: +8.0%
Continue Research